Trials / Completed
CompletedNCT00813969
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing MS) and evidence of involvement of the anterior afferent visual system.
Conditions
- Relapsing-Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Progressive Relapsing Multiple Sclerosis
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous mesenchymal stem cell transplantation | A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-01-01
- Completion
- 2014-05-01
- First posted
- 2008-12-23
- Last updated
- 2016-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00813969. Inclusion in this directory is not an endorsement.